Your session is about to expire
← Back to Search
CHK1 Inhibitor for Lung Cancer (POTENTIATE Trial)
POTENTIATE Trial Summary
This trial is researching a potential new cancer treatment to see how safe and effective it is.
POTENTIATE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.POTENTIATE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had cancer before, but it fits the study's exceptions.My cancer has specific gene changes known to help it grow.I have a history of hepatitis B, hepatitis C, or HIV.I have a serious heart condition.I have or had lung inflammation or scarring that needed strong medication.I have had an organ or bone marrow transplant.My cancer has spread, doesn't respond to treatment, and can't be surgically removed.My cancer shows gene changes that make it grow faster.My cancer shows a high level of normal EGFR.My cancer shows a high level of FGFR1-4 without mutations.I am fully active or restricted in physically strenuous activity but can do light work.My blood counts are within a healthy range.My liver and kidneys are working well.I do not have active brain cancer or symptoms from cancer spread to my brain, with some exceptions.I have previously been treated with EGFR inhibitors.I have a blood cancer.I have previously been treated with CHK1 inhibitors.I have previously been treated with FGFR inhibitors.
- Group 1: Single Agent Dose Escalation
- Group 2: Single Agent Dose Expansion
- Group 3: Dose Escalation in Combination with EGFR Inhibitor
- Group 4: Dose Escalation in Combination with FGFR Inhibitor
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment still possible for this scientific investigation?
"According to the clinicaltrials.gov website, this medical trial is currently accepting applicants since April 24th of 2023 and was last updated on the 25th of that month."
Has the FDA sanctioned any dosage increments of single agent therapy?
"As Single Agent Therapy Dose Escalation is undergoing its initial trial period, there is limited evidence of safety or efficacy. Therefore, it was attributed a score of 1 on our rating system at Power."
To what extent is this medical experiment being populated?
"Affirmative. According to the details on clinicaltrials.gov, this medical experiment was posted on April 24th 2023 and has been actively seeking volunteers since then. 47 patients are needed between 3 trial sites."
What overall outcome is this research project attempting to achieve?
"The trial, which will be monitored over the cycle of one month (28 days), aims to establish Maximum Tolerable Dose and Recommended Phase 2 Dose for BBI-355. Secondary objectives include determining Ctrough, Tmax, and AUC concentrations of the drug in question."
Share this study with friends
Copy Link
Messenger